Table 1.
Baseline characteristics of patients undergoing treatment with IST
| Age | |
|---|---|
| Paediatric ≤ 15 years | 131 (19.4%) |
| Adult > 15 years | 546 (80.6%) |
| 16–30 years | 187 (27.6%) |
| 31–50 years | 203 (30%) |
| > 50 years | 156 (23%) |
| Total | 677 |
| Median age (in years) | 33 (1–83) |
| Sex | |
| Male | 434 (64.1%) |
| Female | 243 (35.9%) |
| Severity | |
| Non-severe (NSAA) | 166 (24.5%) |
| Severe (SAA) | 385 (56.9%) |
| Very severe (VSAA) | 126 (18.6%) |
| PNH clone | |
| Present | 49 (7.2%) |
| Absent | 417 (61.6%) |
| Unknown | 211 (31.2%) |
| Previous treatment | |
| Treatment naive | 443 (65.5%) |
| Stanazolol/danazol | 33 (4.9%) |
| Prednisolone | 85 (12.5%) |
| Cyclosporine | 114 (16.8%) |
| Others | 2 (0.3%) |
| Immunosuppressive therapy | |
| ATG (Anti Thymocyte Globulin) | 424 (62.6%) |
| ALG (Anti Lymphocyte Globulin) | 253 (37.4%) |
| Diabetes—pre-existing/therapy-induced | |
| Yes | 128 (18.9%) |
| No | 549 (18.9%) |
| Serum sickness | |
| Yes | 171 (25.3%) |
| No | 506 (74.7%) |
| Time from diagnosis to starting ATG/ALG | |
| Median (Range) | 1 month (0–189 months) |
| Mean | 4 months |